Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction

Abstract (PubMed)

We performed a randomized, double-blind trial involving patients recruited within 30 days after a myocardial infarction. Patients were assigned to receive either low-dose colchicine (0.5 mg once daily) or placebo. The primary efficacy end point was a composite of death from cardiovascular causes, resuscitated cardiac arrest, myocardial infarction, stroke, or urgent hospitalization for angina. A total of 4745 patients were enrolled with a median follow-up of 22.6 months. The primary end point occurred in 5.5% of colchicine patients versus 7.1% of placebo patients (HR 0.77; 95% CI 0.61-0.96; P=0.02). Low-dose colchicine significantly reduced cardiovascular events after myocardial infarction.